Hanmi PharmaceuticalㆍJW Pharmaceutical Corp. Pfd. Series 2 in the top 100 even with a single-digit growth
[Newsmp] While a sharp wind hit the stock market in 2022, pharmaceutical stocks were also unable to escape the cold wave.
There were only five pharmaceutical stocks in the top 100 in stock price growth on the KOSPI market, and only three of them recorded double-digit growth.
Stock prices of 51 out of 59 pharmaceutical stocks declined from the end of last year, and 23 stocks fell by more than 30%.
Among 59 pharmaceutical-related stocks, Il Dong Holdings had the highest stock price increase this year, recording a 36.1% increase, ranking 33rd out of 933 stocks in the KOSPI market (excluding newly listed and delisted stocks). Il Dong Holdings was the only pharmaceutical-related stock to enter the top 50.
Followed by Il Dong Holdings, Daewon Pharmaceutical placed in 68th with 15.6%, Ilsung Pharmaceutical in 71st with 14.4%, Hanmi Pharmaceutical in 89th with 9.9% and JW Pharmaceutical Corp. Pfd. Series 2 in 97th with 7.6%.
Daewoong Pharmaceutical sat in 102nd with 7.1% growth, Shin Poong Pharmaceutical Co. Ltd. Pfd. Series 1 in 120th with 3.9% and Samil Pharmaceutical in 126th with 2.9%, leading eight pharmaceutical stocks to enter the top 150.
Whanin Pharmaceutical, Samjin Pharmaceutical, Yuhan Corporation Pfd. Series 1, Yuhan Corporation, Jeil Pharma Holdings and JW Pharmaceutical Corp. Pfd. Series 1 defended their fall to less than 5% and ranked in the top 200.
Kukje Pharma, Kyongbo Pharmaceutical, Samsung Biologics and Hana Pharm placed in the top 300 with a drop of less than 10% with Dong-A Socio Holdings of 11.7% and JW Life Science of 12.3%.
Moreover, JW Holdings, Pharmicell, Dong-A ST, Il Dong Pharmaceutical, HanAll Biopharma, Celltrion, Yuyu Pharma Inc. Pfd. Series 2, JW Pharmaceutical, Hyundai Pharmaceutical and Kwang Dong Pharmaceutical recorded a double-digit drop, but they were ahead of the middle among the 933 stocks.
Dongsung Pharmaceutical, Yuyu Pharma, Yuyu Pharma Inc. Pfd. Series 1, Chong Kun Dang Pharmaceutical, Handok and Il-Yang Pharmaceutical Co. Ltd. Pfd. Series 1 fell 20~30%, while Chong Kun Dang Holdings, Il-Yang Pharmaceutical, Bukwang Pharmaceutical, Shin Poong Pharmaceutical, Daewoong, Green Cross Holdings Corp. Pfd. Series 2, PharmGen Science, Green Cross Holdings, Boryung Pharmaceutical, Jeil Pharmaceutical, Yungjin Pharmaceutical, Hanmi Science, Reyon Pharmaceutical and Myungmoon Pharmaceutical slumped 30~40%.
Green Cross, CKD Bio, Aprogen Pharmaceuticals, Samsung Pharmaceutical and ORIENTBIO recorded a 40~50% drop, and Korea United Pharmaceutical, Gene One Life Science and SK Bioscience plunged more than 50%.
